Incomplete remission in depression: Role of psychiatric and somatic comorbidity

Dialogues in Clinical Neuroscience

Volumn 10, Issue 4, 2008, Pages 453-460

  Otte, Christian ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antidepressant; Clinical trial; Comorbidity; Depression; Predictor; Remission; Response

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE;

ALCOHOLISM; ANGINA PECTORIS; ANXIETY DISORDER; ARTHRITIS; ARTICLE; ASTHMA; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISABILITY; DISEASE ASSOCIATION; DRUG ABUSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MEDICAL RESEARCH; MENTAL DISEASE; PANIC; PATIENT SELECTION; PERSONALITY DISORDER; PREVALENCE; PSYCHOTHERAPY; REMISSION; SOCIAL PHOBIA; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; COMORBIDITY; DEPRESSIVE DISORDER; HUMANS; MENTAL DISORDERS;

EID: 59149103043     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370:851.
2. Mathers C, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLOS Med. 2006;3:e442.
3. Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry. 2000;157:229-233.
4. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998;55:694-700.
5. Whooley MA. Depression and cardiovascular disease: healing the broken-hearted. JAMA. 2006;295:2874-2881.
6. Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA. 2003;289:3152-3160.
7. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
8. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
9. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the national epidemiologic survey on alcoholism and related conditions. Arch Gen Psychiatry. 2005;62:1097-1106.
10. Zimmerman M, Chelminski I, McDermut W. Major depressive disorder and axis I diagnostic comorbidity. J Clin Psychiatry. 2002;63:187-193.
11. Melartin T, Rytsälä H, Leskelä U, Lestelä-Mielonen P, Sokero T, Isometsä E. Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study. J Clin Psychiatry. 2002; 63:126-34.
12. Rush AJ. STAR*D: what have we learned? Am J Psychiatry. 2007;164:201-204.
13. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report. Am J Psychiatry. 2008;165:342-351.
14. Paykel ES. Depressive typologies and response to amitriptyline. Br J Psychiatry. 1972;120:147-156.
15. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF. Major depressive subtypes and treatment response. Biol Psychiatry. 1997;42:568.
16. Clayton PJ, Grove WM, Coryell W, Keller M, Hirschfeld R, Fawcett J. Follow-up and family study of anxious depression. Am J Psychiatry. 1991;148:1512-1517.
17. Flint A, Rifat S. Anxious depression in elderly patients. Response to antidepressant treatment. Am J Geriatric Psychiatry. 1997;5:107-115.
18. Brown C, Schulberg HC, Madonia MJ, Shear MK, Houck PR. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry. 1996;153:1293-1300.
19. Gaynes BN, Magruder KM, Burns BJ, Wagner HR, Yarnall KSH, Broadhead WE. Does a coexisting anxiety disorder predict persistence of depressive illness in primary care patients with major depression? Gen Hosp Psychiatry. 1999;21:158.
20. Feske U, Frank E, Kupfer DJ, Shear MK, Weaver E. Anxiety as a predictor of response to interpersonal psychotherapy for recurrent major depression: An exploratory investigation. Depression Anxiety. 1998;8:135-141.
21. Melartin T, Rytsälä H, Leskelä U, Lestelä-Mielonen P, Sokero T, Isometsä E. Severity and comorbidity predict episode duration and recurrence of DSM-IV major depressive disorder. J Clin Psychiatry. 2004;65:810-819.
22. Holma K, Holma I, Melartin T, Rytsälä H, Isometsä E. Long-term outcome of major depressive disorder in psychiatric patients is variable. J Clin Psychiatry. 2008;69:196-205.
23. Eaton WW, Shao H, Nestadt G, Lee BH, Bienvenu OJ, Zandi P. Population-based Study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry. 2008;65:513-520.
24. Tollefson G, Holman S, Sayler M, Potvin J. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry. 1994;55:50-59.
25. Rudolph R, Entsuah R, Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychiatry. 1998;18:136-144.
26. Fawcett J, Barkin R. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry. 1998;59:123-127.
27. Russell M KL, Rush J, Hirschfeld R, et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety. 2001;13:18-27.
28. Joffe RT, Bagby RM, Levitt A. Anxious and nonanxious depression. Am J Psychiatry, 1993;150:1257-1258.
29. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004;291:1887-1896.
30. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287:1840-1847.
31. Akiskal H. Factors associated with incomplete recovery in primary depressive illness. J Clin Psychiatry. 1982;43:266-271.
32. Ostacher M. Comorbid alcohol and substance abuse dependence in depression: impact on the outcome of antidepressant treatment. Psych Clin N Am. 2007;30:69-76.
33. Koenig H, Goli V, Shelp F, et al. Antidepressant use in elderly medical inpatients: lessons from an attempted clinical trial. J Gen Intern Med. 1989;4:498-505.
34. Popkin MK, Callies AL, Mackenzie TB. The outcome of antidepressant use in the medically ill. Arch Gen Psychiatry. 1985;42:1160-1163.
35. Gill D, Hatcher S. Antidepressants for depression in medical illness. Cochrane Database Syst Rev. 2000:CD001312.
36. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701-709.
37. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289:3106-3116.
38. Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial. JAMA. 2007;297:367-379.
39. Lustman PJ, Clouse RE, Nix BD, et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:521-529.
40. Robinson RG, Jorge RE, Moser DJ, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA. 2008;299:2391-2400.
41. Swindle R, Cronkite R, Moos R. Risk factors for sustained nonremission of depressive symptoms: a 4-year follow-up. J Nerv Ment Dis. 1998; 186:462-469.
42. Iosifescu DV, Nierenberg AA, Alpert JE, et al. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry. 2003;160:2122-2127.
43. Pedis RH, Iosifescu DV, Alpert J. Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. Psychosomatics. 2004;45:224-229.
44. Corey-Lisle PK, Nash R, Stang P, Swindle R. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med. 2004;164:1197-1204.
45. Koike AK, Unutzer J, Wells KB. Improving the care for depression in patients with comorbid medical illness. Am J Psychiatry. 2002;159:1738-1745.
46. Papakostas G, Petersen T, Iosifescu D, et al. Obesity among outpatients with Major Depressive Disorder. Int J Neuropsychopharmacol. 2005;8:59-63.
47. Kloiber S, Ising M, Reppermund S, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiatry. 2007;62:321.
48. Krishnan KRR. Comorbidity and depression treatment. Biol Psychiatry. 2003;53:701-706.
49. Wise T, Wiltse C, Iosifescu D, Sheridan M, Xu J, Raskin J. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Int J Clin Practice. 2007;61:1283-1293.
50. Steffens D, Doraiswamy P, McQuoid D. Bupropion SR in the naturalistic treatment of elderly patients with major depression. Int J Geriatric Psychiatry. 2001;16:862-865.
51. Small G, Birkett M, Meyers B, Koran L, Bystritsky A, Nemeroff C. Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group. J Am Geriatr Soc. 1996;44:1220-1225.
52. Papakostas GI, Petersen T, Iosifescu DV, et al. Axis III disorders in treatment-resistant major depressive disorder. Psychiatry Research. 2003;118:183.
53. Reynolds CF, III, Dew MA, Pollock BG, et al. Maintenance treatment of major depression in old age. N Engl J Med. 2006;354:1130-1138.
54. Iosifescu D. Treating depression in the medically Ill. Psychiatric Clin N Am. 2007:77-90.
55. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry. 2002;159:469-473.
56. Zetin M, Hoepner C. Relevance of exclusion criteria in antidepressant clinical trials: a replication study. J Clin Psychopharmacol. 2007;27:295-301.
57. Blanco C OM, Goodwin RD, Ogburn E, Liebowitz MR, Nunes EV, Hasin DS. Generalizability of clinical trial results for major depression to community samples. J Clin Psychiatry. 2008:Jun 10:e1-e5. [Epub ahead of print].
58. Partonen T SS, Lönnqvist JK. Patients excluded from an antidepressant efficacy trial. J Clin Psychiatry. 1996;57:572-575.